Intelligent Bio Advances FDA 510(k) with Cybersecurity
NEW YORK, April 17, 2026 Intelligent Bio Solutions Inc. (INBS) has strengthened its upcoming FDA 510(k) submission by successfully...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
NEW YORK, April 17, 2026 Intelligent Bio Solutions Inc. (INBS) has strengthened its upcoming FDA 510(k) submission by successfully...
NEW YORK | December 31, 2025 — Intelligent Bio Solutions announced a strategic manufacturing partnership with Syrma Johari MedTech,...
